Surgery Techniques for Ulnar Nerve Entrapment
Trial Summary
What is the purpose of this trial?
This trial aims to determine which of two surgeries is more effective in treating ulnar neuropathy at the elbow and reducing symptoms.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for ulnar nerve entrapment?
Research shows that both simple decompression and anterior transposition are effective treatments for ulnar nerve entrapment at the elbow. Studies indicate that simple decompression can be as effective as anterior transposition, especially for less severe cases, while modified submuscular transposition may be better for more severe cases.12345
Is surgery for ulnar nerve entrapment generally safe?
Research shows that surgeries like simple decompression and anterior transposition for ulnar nerve entrapment are generally safe, with improvements in nerve function observed after surgery. These techniques have been studied in many patients and are considered effective and safe for treating this condition.12345
How does the treatment for ulnar nerve entrapment differ from other treatments?
The treatment for ulnar nerve entrapment, which includes simple decompression and subcutaneous anterior transposition, is unique because it can be performed using minimally invasive techniques, such as endoscopic decompression, which may offer similar effectiveness to more invasive methods. Additionally, for mild cases (grade I), subcutaneous transposition is recommended, while more severe cases (grades II and III) may benefit more from modified submuscular transposition.12678
Research Team
Kevin Chung, MD, MS
Principal Investigator
University of Michigan
Eligibility Criteria
This trial is for people with ulnar nerve entrapment at the elbow who have tried non-surgical treatments like night splinting. They must meet specific diagnostic criteria and be able to follow study procedures. It's not for those with previous elbow surgery, other neuropathies, or conditions that make surgery too risky.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Surgery
Participants undergo one of two surgical procedures: subcutaneous anterior transposition or simple decompression
Post-Surgery Follow-up
Participants are monitored for recovery and complications at various time points
Treatment Details
Interventions
- Simple decompression (Procedure)
- Subcutaneous anterior transposition (Procedure)
Simple decompression is already approved in Canada for the following indications:
- Ulnar neuropathy at the elbow (UNE)
- Cubital tunnel syndrome
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Michigan
Lead Sponsor
Marschall S. Runge
University of Michigan
Chief Executive Officer since 2015
MD, PhD
Karen McConnell
University of Michigan
Chief Medical Officer since 2020
MD
University of Oklahoma
Collaborator
Dr. Scott Rollins
University of Oklahoma
Chief Executive Officer since 2016
PhD in Immunology from the University of Oklahoma
Dr. Ondria Gleason
University of Oklahoma
Chief Medical Officer
MD from the University of Oklahoma College of Medicine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator
Dr. Lindsey A. Criswell
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Director since 2021
MD, MPH, DSc
Dr. Robert Colbert
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Clinical Director since 2014
MD
Curtis National Hand Center
Collaborator
Emory Healthcare
Collaborator
Ohio State University
Collaborator
Dr. John J. Warner
Ohio State University
Chief Executive Officer since 2023
MD, MBA
Dr. Peter Mohler
Ohio State University
Chief Medical Officer since 2023
PhD in Molecular Biology
University of Pittsburgh Medical Center
Collaborator
Leslie C. Davis
University of Pittsburgh Medical Center
Chief Executive Officer since 2021
BA in Economics from Wesleyan University, MBA in Health Administration from The Wharton School
Don Yealy
University of Pittsburgh Medical Center
Chief Medical Officer since 2023
MD from the Pritzker School of Medicine, University of Chicago
Norton Healthcare
Collaborator
OrthoCarolina Research Institute, Inc.
Collaborator
Wake Forest University Health Sciences
Collaborator
Dr. L. Ebony Boulware
Wake Forest University Health Sciences
Chief Medical Officer since 2022
MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health
Dr. Julie Ann Freischlag
Wake Forest University Health Sciences
Chief Executive Officer since 2020
BS from University of Illinois, MD from Rush University